In conclusion, the identification of CXCL5 as a key driver in HCC progression offers an innovative therapeutic approach that directly interferes with disease progression in TGF‐β/CXCL5‐positive patients. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.